science
plus
.abes.fr
|
explorer
À propos de :
Schuitemaker Hanneke
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
foaf:Person
, within Data Space :
scienceplus.abes.fr
associated with source
document(s)
Type:
Person
New Facet based on Instances of this Class
Attributs
Valeurs
type
Person
name
Schuitemaker Hanneke
personal mailbox
J_Schuitemaker@CLB.nl
h.schuitemaker@amc.uva.nl
j_schuitemaker@clb.nl
h.schuitemaker@sanquin.nl
H.Schuitemaker@sanquin.nl
familyName
Schuitemaker
Given name
Hanneke
is
relates
of
http://hub.abes.fr/oup/periodical/cid/2010/volume_50/issue_9/101086651687/authorship/6
http://hub.abes.fr/oup/periodical/jid/2005/volume_191/issue_12/101086430506/authorship/8
http://hub.abes.fr/oup/periodical/jid/2002/volume_186/issue_12/101086345677/authorship/5
http://hub.abes.fr/oup/periodical/jid/2005/volume_191/issue_5/101086427559/authorship/8
http://hub.abes.fr/oup/periodical/jid/2003/volume_187/issue_9/101086374650/authorship/4
http://hub.abes.fr/oup/periodical/jid/2003/volume_188/issue_6/101086377105/authorship/7
http://hub.abes.fr/oup/periodical/jid/2008/volume_197/issue_6/101086528695/authorship/8
http://hub.abes.fr/oup/periodical/jid/2010/volume_202/issue_6/101086655782/authorship/29
http://hub.abes.fr/oup/periodical/cid/2008/volume_47/issue_11/101086592978/authorship/5
http://hub.abes.fr/oup/periodical/jid/1999/volume_179/issue_4/101086314658/authorship/6
http://hub.abes.fr/oup/periodical/jid/2010/volume_201/issue_7/101086651144/authorship/7
http://hub.abes.fr/oup/periodical/jid/1998/volume_178/issue_6/101086314522/authorship/6
is
Contributor
of
A Nonprogressive Clinical Course in HIV-Infected Individuals Expressing Human Leukocyte Antigen B57/5801 Is Associated with Preserved CD8+ T Lymphocyte Responsiveness to the HW9 Epitope in Nef
is
Author
of
GB Virus C Coinfection and HIV-1 Disease Progression: The Amsterdam Cohort Study
Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS
CC Chemokine Receptor 5 Δ32 and CC Chemokine Receptor 2 64I Polymorphisms Do Not Influence the Virologic and Immunologic Response to Antiretroviral Combination Therapy in Human Immunodeficiency Virus Type 1-Infected Patients
Reply to George and to Stapleton et al
Recovery of Viremic Control after Superinfection with Pathogenic HIV Type 1 in a Long-Term Elite Controller of HIV Type 1 Infection
Increased In Vitro Cytopathicity of CC Chemokine Receptor 5-Restricted Human Immunodeficiency Virus Type 1 Primary Isolates Correlates with a Progressive Clinical Course of Infection
Decreasing Sensitivity to RANTES (Regulated on Activation, Normally T Cell-Expressed and -Secreted) Neutralization of CC Chemokine Receptor 5-Using, Non-Syncytium-Inducing Virus Variants in the Course of Human Immunodeficiency Virus Type 1 Infection
Absence of HIV-1 Superinfection 1 Year after Infection between 1985 and 1997 Coincides with a Reduction in Sexual Risk Behavior in the Seroincident Amsterdam Cohort of Homosexual Men
No Evidence for an Effect of the CCR5 Δ32/+ and CCR2b 64I/+ Mutations on Human Immunodeficiency Virus (HIV)-1 Disease Progression among HIV-1-Infected Injecting Drug Users
Cross-Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression
Role of CCR2 Genotype in the Clinical Course of Syncytium-Inducing (SI) or Non-SI Human Immunodeficiency Virus Type 1 Infection and in the Time to Conversion to SI Virus Variants
Alternative Linked Data Documents:
ODE
Content Formats:
RDF
ODATA
Microdata
